239862
32 posts


@Sheep_Esports Need to test their testosteron levels should be near 0
English

@drewlevin Please unban my account that was banned 8 years ago. I still refuse to let it go. It was my first account. It has alot of value to me
English

@MartinShkreli @SimoneSyed Shkreli hitting on some broad on twitter, respect
English

Something whose legacy is only tiktok edits and video essays.
JOLLY J✨@DynamoSuperX
what game is this? lowkey, I've only seen people ask this about graphics and story.
English

@fireworkstrades @BioStocks It means that $EQ made RA's restricted shares (which they got for $35 mil) TRADABLE. It means they are able to sell it. It does not mean they ARE selling them. This is normal PIPE stuff
English

@Change8765432 @BioStocks then what is it? what does files to sell mean?
English

@BioStocks ? Are They selling there shares which they recently bought? $EQ
English

@Biotech2k1 Why buy $abvx for 20 billion when they can buy $EQ for 1 billion?
English

$1.90 on 8/22 to 0.96 today. not surprised. $eq
financebully@financebully
@MartinShkreli the lead program is pre-clin and they're the only one who states their program is similar to $abvx in order to attract buyers. the company mgmt and bod are b-c rated and they've been pivoting using public market since 2018. maybe a quick flip due to hype, but hard pass for me.
English

@somewheresy why compound anything? just get an rx lol
English

@MartinShkreli @wager_monster I saw you write this tweet on stream, I WAS THERE
English

@wager_monster one creates tremendous value for society, one destroys it. how dumb can you be?
English

The pharmaceutical patents have to be banned. There is no other way.
Martin Shkreli@MartinShkreli
the sports betting markets (they're not "prediction" markets) have to be banned. there is no other way.
English

Another portfolio update!
Added: $SPRB (l), $QURE (l), $LRMR (l), $ALDX (s)
Unchanged: $BBIO (l), $SLNO (l)
Closed: $GOSS (s), $QURE (s), $CRNX (l)
Some developments since my last update. $SPRB I took a small short, then flipped long again around ~$55. At my new average, I see very little downside. This is an incredibly rare indication with not many treatment alternatives, and $DNLI PDUFA should read through. Holding out for that as well as the Q4 filing. There is also the possibility of another Shkreli pump…but that’s not exactly part of the thesis. Some dilution risk here, but in the 50s I couldn’t pass it up. This could be a $100+ stock by the end of the year.
$QURE is strictly regulatory now that Prasad is out. I still don’t believe the drug works, and I still maintain some doubts about how much Prasad’s departure will affect it. However, the stock is beaten down to a point that any positive news will send it flying. If the FDA makes any change to their decision, even if only a willingness to review the data…that will likely be enough to move price significantly. This one is purely a regulatory gamble and again, has nothing to do with efficacy of AMT-130 or fundamentals. Proceed at your own risk.
$LRMR is another one that caught the Prasad ouster pump. Recently it dipped below offering price and I took the opportunity to enter. Single asset company focused on FA, but would become the only truly disease modifying treatment on the market if approved. I have some doubts as to whether this would work in an RCT, but with the slew of designations (START included) I think we will see a conditional approval. By the time any further efficacy proof is required, I intend to be out.
$ALDX The FDA typically asks for more data when a major risk needs to be addressed. They had two data sets, and have characterized it as the FDA asking them to submit ONLY the positive data. This is unlikely to be true, and if the FDA is now asking for more, that leaves them with only a negative data set (their words) to submit. I don’t see how this new information will lead to anything but a CRL.
$GOSS and $QURE shorts went well and have been closed. My unchanged positions $BBIO and $SLNO still maintain their long term theses, but unfortunately $CRNX did not make the cut. In the current environment, I decided I didn’t want to have too much money wrapped up in launch stories.
The play here for me moving forward is continuing to hold a majority cash and focusing on binaries while macro/geopolitical pressures work themselves out. Biotech is likely to get hit hard as a speculative sector, and I’d like to minimize my exposure to that possibility as much as I can.
As always, thanks for keeping up with me, and I’m always looking for new stocks and new topics to explore if anyone has ideas to share.
English















